Global Sickle-Cell Disease Treatment Market By Treatment (Pharmacotherapy, Blood Transfusion, and Bone Marrow Transplant), By End-User (Hospitals, Specialty Clinics, and Other End-Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Sickle Cell Disease Treatment Market Overview:

The global market for Sickle-Cell Disease (SCD) Treatment was worth USD 1,903.2 million in 2021 and is forecast to experience a 17.9% CAGR during 2023-2032.

Sickle cell disease is a blood disorder that is inherited by hereditary, that causes rigid, abnormal, sickle-shaped blood cells (RBCs). It is caused by mutations within the beta-globin genes. The severity of the condition varies from person to person.

Global Sickle-Cell Disease Treatment Market Analysis

Treatment Analysis

There are currently two options for sickle-cell disease treatment: palliative and symptomatic. SCD patients aged 16 and under can receive bone marrow donation. However, this is not a curative treatment. The risks of BMT in adults make it difficult for younger patients to have the procedure. Treatments include blood transfusions and medications to prevent or reduce complications.

Endari and Hydroxyurea remain the only approved drugs to treat SCD. A potential launch of promising candidates such as voxelotor (GBT 440), rivipansel, crizanlizumab, and Altemia will support the rapid growth of pharmacotherapy in sickle-cell disease treatment.

With a market share of over 48%, blood transfusion was the dominant treatment for sickle cell diseases. However, pharmacotherapy is expected to be the leader of the market by 2032 due to its strong pipeline and numerous promising drug launches during the forecast period.

End-User Analysis

The hospital segment will dominate the market during the forecast period. A volatile organic compound is a major reason for hospital admissions. It accounts for approximately 250, 000 emergency room visits per year in the US. This will favor the expansion and development of the hospital segment over the forecast period.

The growth of specialty clinics is being driven by the growing number of clinics. There are also frequent outpatient visits because SCD is often associated with multiple manifestations. This is another reason this segment has grown. The rising number of drug-using patients is driving the growth of care at home. This is likely to increase the growth in the other segments.

Key Market Segments

By Treatment

• Pharmacotherapy
• Blood Transfusion
• Bone Marrow Transplant

By End-User

• Hospitals
• Specialty Clinics
• Other End-Users

Market Dynamics

There are many types of sickle cell anemia. These can be genotypic or phenotypic depending on the mutations in hemoglobin genes. About 300,000 children are born each year with the disease. People of Middle Eastern, African, or South Asian descent often have sickle cell disease.

Global market growth is expected to be driven by improved healthcare, increased immigration, and a large population of African-Americans. The current treatment of chronic SCD primarily involves hydroxyurea injections and blood transfusions. A majority of patients are allergic to hydroxyurea. Patients with no resistance to hydroxyurea offer limited benefits and carry long-term safety risks.

Patients who have received blood transfusions can be exposed to blood-borne infections, iron overload, fever, and allergic reactions. Around 25% of patients suffering from sickle cell disease are transfusion-dependent. BMT is the only curative treatment.

However, it’s only recommended for a very small proportion of patients. Hydroxyurea was FDA-approved as a treatment for SCD until 2017. It was known under the names Droxia and Hydrea. Endari by Emmaus Life Sciences was approved by the FDA for the treatment of severe complications in SCD. It is available for both pediatric and adult patients. Endari was the FDA’s second approved drug.

The favorable government policies, increasing awareness of hematological cancers, increased investment, and improved healthcare infrastructure are expected to drive lucrative growth in emerging markets such as Nigeria and South Africa.

Regional Analysis

North America held a dominant position in the global sickle cell anemia treatment market, with a 36% share in 2021. France is followed closely by the U.K. France is expected to see a CAGR of almost 18% but the U.S. will continue to hold its lead position throughout the forecast period. This could be due to factors like the possible launch of pipeline drugs and increased adoption of novel therapeutics.

The European migrant crises, which led to an increase of immigrant people from Africa, South Asia, and Western Asia, are major factors driving the market in EU5 markets. The seven main markets will expand at a cumulative CAGR of more than 17%.

Key Regions and Countries covered іn thе rероrt:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• MEA
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Market Share & Key Players Analysis:

Emmaus Medical, Inc., Global Blood Therapeutics, Inc., bluebird bio, Inc., Pfizer, Inc., Novartis AG, and Novartis AG are just a few of the players that operate in the sickle cells anemia market. Endari’s strong sales are expected to propel Emmaus Medical into the top spot in 2023. Global Blood Therapeutics Sancilio has the potential to capture a significant market share once their pipeline candidates-voxelotors or Altemia are approved.

The promising results of late-stage pipeline drugs, such as Novartis’ crizanlizumab from Novartis and Pfizer’s Rivipansel from Pfizer, have also been demonstrated. Market growth is expected to be positive with the introduction of disruptive therapeutics, such as Modus Therapeutics’ Sevuparin and Prolong Pharmaceuticals’ Sanguine. In the near future, gene therapies will be introduced to the sickle-cell disease treatment market, such as Bluebird Bio’s Lentiglobin, Bellicum Pharmaceuticals BPX 501, and Gamida Cells’ Cordin.

Маrkеt Кеу Рlауеrѕ:

• Emmaus Medical Inc.
• Pfizer Inc.
• Blood Therapeutics Inc.
• Bluebird bio Inc.
• Novartis AG.
• AstraZeneca Plc
• Eli Lilly
• Baxter International Inc.
• Other Key Players

For the Sickle Cell Disease Treatment Market research study, the following years have been considered to estimate the market size: